buyModerate cluster of 3
Paul L Berns bought $14M of MTSR
director at Metsera, Inc.. 789,998 shares at an average of $18.00, traded Feb 3, 2025, filed Feb 3, 2025.
Conviction score
58Value
$14M
789,998 shares
Holdings after
8,313,680
+11% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$14.2M at market
- +3Relative to holdingsHoldings up 11%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-012583, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 3, 2025 | CConversion Common Stockindirect: See footnote | +7,523,682 | - | - | 7,523,682 | Feb 3, 2025 |
| Feb 3, 2025 | POpen-market purchase Common Stockindirect: See footnote | +789,998 | $18.00 | $14M | 8,313,680 | Feb 3, 2025 |
| Feb 3, 2025 | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
Related signals
Other insiders at Metsera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | MTSRsell Metsera, Inc. | Fmr LLC owner, other | $9,648 268 shares | -100% | |
| 50Moderate | Metsera, Inc. | ARCH Venture Partners XII, LLC owner | $40M 2,222,222 shares | +13% | |
| 58Moderate | Metsera, Inc. | Kristina Burow director, owner | $40M 2,222,222 shares | +13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.